Adherence to anti-seizure medications among pediatric epilepsy patients during the Sudan armed conflict

Aseel Adil Ahmed Abdelhafiz1, Alag Adil Ahmed Abdelhafiz2, Khalid Osman Mohamed3

  • 1Faculty of Medicine, University of Khartoum, Khartoum, Sudan. aseeladelahmed1@gmail.com.

Conflict and Health
|March 17, 2026
PubMed

Insights

Pediatric epilepsy patients in Sudan show low adherence to antiseizure medications (ASMs) during conflict, with medication unavailability and transport issues being major barriers. Interventions are urgently needed to improve epilepsy management.

Area of Science:

  • Neurology
  • Public Health
  • Pediatrics

Background:

  • Poor adherence to antiseizure medications (ASMs) contributes significantly to breakthrough seizures in epilepsy.
  • Evaluating ASM adherence in pediatric epilepsy patients during armed conflict in Sudan is crucial for understanding management challenges.

Purpose of the Study:

  • To assess the adherence rates of pediatric epilepsy patients to ASMs amidst armed conflict in Sudan.
  • To identify factors influencing medication adherence and challenges faced by caregivers.

Main Methods:

  • An observational, analytical cross-sectional study involving pediatric epilepsy patients (≤18 years) in Sudan.
  • Data collected via phone interviews using the Medication Adherence Rating Scale (MAR-20) and Pediatric Epilepsy Side Effects Questionnaire (PESQ).
  • Statistical analysis included chi-square, Fisher's exact, and Mann-Whitney U tests.

Main Results:

  • Only 31.1% of 161 pediatric patients achieved complete ASM adherence; 68.9% were nonadherent.
  • Key barriers included medication unavailability (39.1%) and lack of transportation (32.9%).
  • Nonadherence was linked to increased seizure frequency and higher reported side effects, particularly cognitive issues.

Conclusions:

  • Low ASM adherence rates among pediatric epilepsy patients in Sudan during conflict highlight significant healthcare challenges.
  • Economic hardship, displacement, and disrupted medical services impede effective epilepsy management.
  • Multifaceted interventions addressing healthcare system barriers and caregiver support are essential.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
360
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
902
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.2K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
423